Top 40 Life Science VC (Venture Capital) Funds in Belgium in December 2024
A list of 40 VC (Venture Capital) funds that invest in Life science startups based in Belgium. We rank investors based on the number of investments they made in Life science companies from Belgium. We update this investor list every month.Top 40 Life Science VC (Venture Capital) Funds in Belgium in December 2024
Investor | Life Science Belgium investments |
---|---|
PMV | 6 |
Meusinvest (Noshaq) | 4 |
Qbic Fund | 4 |
Limburgse Reconversie Maatschappij | 3 |
Theodorus III | 3 |
S.R.I.W. | 3 |
Innovation Fund | 3 |
Sambrinvest | 3 |
SFPI-FPIM | 2 |
VIB | 2 |
V-Bio Ventures | 2 |
New Science Ventures | 2 |
Korys | 1 |
Capricorn Partners | 1 |
Smedvig | 1 |
Ifoghas Investments | 1 |
Fund+ | 1 |
Mérieux Equity Partners | 1 |
Novo Nordisk | 1 |
Nausicaa Ventures | 1 |
Epimède SA | 1 |
Qbic | 1 |
Opdorp Finance BVBA | 1 |
OBI SA | 1 |
the SRIW Life Sciences | 1 |
Newton Biocapital | 1 |
Innovation Industries | 1 |
invest.bw | 1 |
Vives Louvain Technology Fund | 1 |
WING by Digital Wallonia | 1 |
VIVES Funds | 1 |
BioGeneration Ventures | 1 |
Industrya | 1 |
Seventure Partners | 1 |
6K Venture Capital | 1 |
European Investment Bank | 1 |
UCB Ventures | 1 |
Nivelinvest | 1 |
Fonds Vives II (University of Louvain, UCL) | 1 |
Merieux Developpement | 1 |
Do and dare company
Show more
Investment focus
- Software, Biotechnology, Health Care
- Series A, Seed, Series B
- Belgium, United States, The Netherlands
Portfolio highlights
- Apideck — Integrate and monitor APIs at warp speed. Apideck is the fastest way for developers to build integrations. Connect new APIs in minutes instead of days.
- Minze Health — Minze Health is a health tech start-up that builds creative digital health solutions for urology, pelvic health, and (in)continence care.
- PanTera — PanTera wants to bring a new hope to cancer patients by enabling the widespread use of radiopharmaceuticals for personalised treatment of tumors
Noshaq offers financial services to help businesses develop.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Funding Round
- Belgium, France, Germany
Portfolio highlights
- Veoware — More coverage, shorter revisit time. Increasing target collection frequency through modular next-gen actuator technology.
- Get Your Way — Discover the future of assisted reality with Get Your Way's aRdent smart glasses. Perfect for SMEs looking for innovative solutions to improve their business
- Brenus Pharma — Brenus Pharma is an allogeneic platform to generate immune therapy ambitioning to harness patient immune system & prevent cancer resistance over treatment.
The Qbic Fund is a multi-sector fund supporting spin-off companies of the Ghent, Brussels and Antwerp university associations and of VITO. Through its strategic partnership with the universities of Ghent, Brussels and Antwerp, and VITO, the Qbic Fund has early and privileged access to promising research projects at these partner universities. Ourinvestment approach is based on early in-depth and independent review and analysis followed by hands on involvement and support.In May 2012 the Qbic Fund held its first close and currently it has over € 30 million under management. The Qbic Fund is backed by several public and private investors and managed by Qbic Venture Partners.
Show more
Investment focus
- Biotechnology, Software, Health Care
- Seed, Funding Round, Series A
- Belgium
Portfolio highlights
- Weavely — Design forms in Figma - publish with Weavely. We turn your visual ideas into interactive, web-based forms.
- Flindr Therapeutics — Immagene develops personalized cancer immunotherapies to fight multiple cancer type.
- Confo Therapeutics — Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO® technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO® body-stabilized active state conformationsof these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.
Oxygen for growth - LRM
Show more
Investment focus
- Information Technology, Software, Biotechnology
- Funding Round, Series A, Seed
- Belgium, United States, The Netherlands
Portfolio highlights
- Cumul.io — Create powerful dashboards in minutes. Share with your teams, or integrate in your platform. Drive growth in your business today!
- MobieTrain — Unlock the potential of your customer-facing employees and create memorable customer experiences with MobieTrain's app.
- Raw Stadia — Raw Stadia is a sports technology company that specializes in surface player interactions.
Theodorus is the spin-off fund of Université Libre de Bruxelles that invests ininvest in early stage projects based on proprietary disruptive technologies.
Show more
Investment focus
- Health Care, Life Science, Medical
- Funding Round, Seed, Series A
- Belgium, Canada, France
Portfolio highlights
- DrugBank — DrugBank augments human intelligence to improve the world’s health. Our suite of products are powered by the world’s most complete and up-to-date pharmaceutical knowledge database. It includes everything there is to know about drugs and how they work in the body. We enable companies to improve healthcare delivery through precision medicine orclinical software applications, as well as uncover insights through data science in drug discovery. Our knowledge base can be integrated into software solutions to help achieve clinical intelligence. Companies can easily scale their usage through our API and launch faster with flexible data modules. By providing users with advanced insights and the right information at the right time, users are empowered to make better health decisions.Our extensive, structured datasets are used to discover novel drug candidates, identify drug repurposing opportunities, and build predictive machine learning models. Companies working with data science can find answers quickly and get drugs to market faster with our evidence-based drug information. Lastly, our publicly available resource, DrugBank Online, is free-to-use with limited datasets available for download for academic and non-commercial researchers. DrugBank has been cited in over 13,000 academic publications and is used by millions of researchers and health professionals globally.
- HypnoVR — HypnoVR is a virtual reality software for anesthesia, treatment of pain, and anxiety. It was founded in 2016 and is based in Strasbourg, France.
- Cascador Health — Cascador Health bridges the gap between sources and users of healthcare data. Using curated, validated and anonymized RWD allows healthcare providers and life science industry to gain insights and provide better care.
The S.R.I.W. Group is an institution at the heart of the financial market that assists entrepreneurs in creating and developing businesses in the Walloon region. It reflects the effort of Wallonian industry in facing the challenges of the creation of economic value in the 21st century.
Since its creation in 1979, the Société Régionaled’Investissement de Wallonie has continuously been expanding its abilities to adapt and anticipate as well as its flexibility in order to meet the requirements of its partners who are confronted with the evolution of the world economy. The principles of good governance, a strong business culture and shared values at the heart of the Group constitute important assets to capture the changing realities of the market and progress in a sustainable development perspective.
Show more
Investment focus
- Biotechnology, Health Care, Manufacturing
- Funding Round, Series A, Series B
- Belgium, United States, Spain
Portfolio highlights
- Univercells — We are biotech innovators, rooted in Belgium, driven by one purpose: To transform how biotech drugs are made so everyone, everywhere, can get them.
- Intressa Vascular — Intressa Vascular provides innovative solutions to address life-threatening cardiovascular conditions such as aortic dissection.
- Santero Therapeutics — Santero Therapeutics seeks to provide novel medications with fresh modes of action that combat diseases with high resistance. Santero develops antimicrobials with novel modes of action to combat the rise of antibiotic-resistant microorganisms.
Chemical, Advanced Materials, Cosmetics, Recycling, CleanTech, Plastics and Rubber Manufacturing, Nanotechnology, Biosciences
Show more
Investment focus
- Health Care, Manufacturing, Information Technology
- Funding Round, Seed, Series A
- Belgium, France, Luxembourg
Portfolio highlights
- Aloxy — Aloxy offers reliable IIot solutions tailored to the needs of the process industry. Our valve sensor provides an open and close indication of manual valves.
- Graftys — Graftys, an Aix-en-Provence, France-based early stage company focused on advanced bone biologics.
- SENSE in — SENSE in manufactures monitoring solutions based on thermomechanical sensors sensitive to deformation, pressure, temperature, humidity, and more. Their solutions evaluate in real time or periodically the expected characteristics and alert on abnormal behavior, threshold overruns, and damage.
Sambrinvest is an active venture capital player in the region of Charleroi - Thuin.
Show more
Investment focus
- Biotechnology, Health Care, Information Technology
- Seed, Series A, Series B
- Belgium, France, Spain
Portfolio highlights
- AdipoPharma — By harnessing the power of the Adipocyte AdipoPharma is committed to developing innovative treatment for type 2 diabetes
- AbolerIS Pharma — AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance.
- ATB Therapeutics — ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.
The Federal Holding and Investment Company (SFPI-FPIM) centrally manages the federal government’s shareholdings, cooperates with the government on specific projects and pursues its own investment policy in the interests of the Belgian economy.
Show more
Investment focus
- Health Care, Biotechnology, Medical Device
- Funding Round, Series B, Series A
- Belgium, United States, France
Portfolio highlights
- Cohabs — We create sustainable & community-driven shared homes around the world for young workers and interns. Join our community.
- Univercells — We are biotech innovators, rooted in Belgium, driven by one purpose: To transform how biotech drugs are made so everyone, everywhere, can get them.
- Tangent Works — Create predictive models in seconds for faster and better forecasting & anomaly detection with TIM InstantML.
Strategic research in on life sciences and biotechnology
Show more
Investment focus
- Biotechnology, Pharmaceutical, Health Care
- Series A, Series B, Funding Round
- Belgium, Brazil, Denmark
Portfolio highlights
- Protealis — Sustainable plant proteins for Europe
- Confo Therapeutics — Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO® technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO® body-stabilized active state conformationsof these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.
- Augustine Therapeutics — Augustine, Innovative therapies for neuromuscular and neurodegenerative diseases
V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biotech, pharmaceutical and agriculturalsectors.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Seed
- Belgium, France, United Kingdom
Portfolio highlights
- ATB Therapeutics — ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.
- Confo Therapeutics — Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO® technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO® body-stabilized active state conformationsof these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.
- Augustine Therapeutics — Augustine, Innovative therapies for neuromuscular and neurodegenerative diseases
New Science Ventures is a venture capital firm that focuses on investments in life sciences and information technology companies. They invest in early and late stage companies taking novel scientific approaches to address significant unmet needs, while creating order-of-magnitude improvements in performances. The company also invests in companiesusing science-based innovations to address market needs in life sciences such as pharmaceuticals, biologics, medical devices, diagnostics, and IT. The team of the company expertise in strategy and corporate planning, operations and cost management, and leadership development.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series D
- United States, United Kingdom, Belgium
Portfolio highlights
- Glydways — Glydways, formerly Wayfarer is a transportation technology and clean energy company based in South San Francisco, California. It specializes in the design, manufacture, installation, and operation of affordable autonomous transportation for low, medium, and extremely high-capacity needs.
- Vuv Analytics — VUV Analytics was incorporated in Austin, TX in December 2009, as a spin-off from a semiconductor equipment company. The five founders bring with them critical and unique know-how related to the hardware, software, analysis, intellectual property, and marketing associated with VUV technologies. The team's past success in pioneering VUVreflectometry for use in the semiconductor metrology field yielded several key market wins and an extensive IP portfolio, including 32 issued patents and 12 pending patents.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
Korys is the name chosen by the Colruyt family for their investment structure. The name Korys is derived from the Latin word for hazelnut tree – Corylus - which is at the origin of the Colruyt name.Their multi-disciplinary approach enables us to create a well-balanced, diversified portfolio of listed stocks and bonds, private equity funds, anddirect participations in small and medium-sized companies. Through their investments, they aim to make a positive impact on people and the planet, while generating attractive returns. A “three P” approach (People, Planet, Profit) forms the cornerstone of their investment strategy. They invest for the long term, as they realize that it takes time to achieve the sustainable impact they are aiming for. They focus their investments in sectors in which they have built substantial expertise as a team: Cleantech, consumer goods & retail and life sciences.
Show more
Investment focus
- Biotechnology, Information Technology, Renewable Energy
- Funding Round, Series A, Series B
- Belgium, The Netherlands, Germany
Portfolio highlights
- Greenely — Greenely is the electricity company that optimizes your electricity use using smart technology in an app. We help you take control of your consumption.
- OroraTech — OroraTech provides global real-time information services. The first target market is early detection and monitoring of wildfires, extended by a proprietary constellation of thermal imaging nanosatellites equipped with in-space AI image processing. At the beginning of 2020, OroraTech launched an MVP called Wildfire Service (WFS) that enables quickdetection and monitoring of wildfires on a global scale. The combination of existing thermal-infrared satellite data with external data layers, such as fuel, wind, and risk maps results in an automatic generation of fire alerts and the display of current fire perimeters for users. The MVP was launched in early 2020 and has gained increasing traction with governmental and large corporate customers all over the world.
- PanTera — PanTera wants to bring a new hope to cancer patients by enabling the widespread use of radiopharmaceuticals for personalised treatment of tumors
Capricorn Partners is a unique independent manager of venture capital, growth capital and quoted equity funds
Show more
Investment focus
- Biotechnology, Health Care, Software
- Funding Round, Series B, Series A
- Belgium, United States, The Netherlands
Portfolio highlights
- Thryve — Thryve’s SDK brings everything you need to access fragmented wearable, medical devices, and health data silos with a single integration. We unify your users’ data from smartwatches, blood glucose meters, and many other sources that unlock a continuous stream of harmonized health information for your care. We support popular data sources like AppleHealth, Google Fit, Huawei Health, Samsung Health, and many more.
- Minze Health — Minze Health is a health tech start-up that builds creative digital health solutions for urology, pelvic health, and (in)continence care.
- Electric Hydrogen — Electric Hydrogen designs and builds low-cost, high-efficiency green hydrogen systems to economically decarbonize industrial sectors like ammonia and steel
Venture Capital firm based in London. We help enable business funding though capital investment. In turn, that funds and drives business growth as exceptional speed. Visit our site to find out how our proven model of business investment can help your start up.
Show more
Investment focus
- Medical, Health Care, Life Science
- Series A
- Belgium
Portfolio highlights
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Ifoghas Investments operates as an investment firm.
Show more
Investment focus
- Medical, Health Care, Life Science
- Series A
- Belgium
Portfolio highlights
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Fund+ is a venture capital firm that invests in companies operating in the diagnostics, therapeutics, medical devices, and life science sectors. The firm wants to create sustainable shareholders' value, contribute to the development of a leadership position in the life sciences sector, and generate a tangible, beneficial societal impact.Fund+ was established in 2015 and is based in Leuven, Belgium.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- Belgium, United States, Spain
Portfolio highlights
- Confo Therapeutics — Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO® technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO® body-stabilized active state conformationsof these receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Mérieux Equity Partners (“MxEP”) is a management company dedicated to venture, growth and LBO investments in the healthcare and nutrition sectors. MxEP actively supports entrepreneurs and industrial companies with differentiated products and services, by providing privileged access to its expertise and international network. MxEP
currently managesmore than €600m AUM and has recently launched a new vehicle MP3 of €350m dedicated to growth/LBO.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Private Equity, Funding Round
- France, Belgium, United Kingdom
Portfolio highlights
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
- Prothea Technologies — Prothea Technologies is a private medical technology business to provide lung cancer biopsy and therapy in a single hospital visit.
- CorFlow Therapeutics AG — CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complicationrates in these patients.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.
Show more
Investment focus
- Biotechnology, Therapeutics, Health Care
- Series A, Series C, Seed
- United States, Denmark, France
Portfolio highlights
- The Sabi — Holistic, all natural skincare and herbal remedies for hormonal balancing. SABI represents a path to feeling well and beautiful, a place for key knowledge transfer and the essential self-care rituals to navigate the female hormonal journey.
- ElevateBio — We provide the tools, time, and environment to innovate and accelerate development of life-saving Cell and gene therapies.
- Tanai Therapeutics — Tanai Therapeutics develops novel therapeutics for people living with obesity and obesity-related complications.
A multi-industry early stage venture capital fund Nausicaa Ventures is an early stage investment fund organisation focused on investment rounds between EUR 1 and 4 million. Nausicaa Ventures was created in 2009 by bringing together 35 private investors and selected institutional investors, such as the European Investment Fund or ING Bank, under the management of ...
Show more
Investment focus
- Software, CRM, Big Data
- Series B, Funding Round
- Belgium
Portfolio highlights
- NGDATA — Unleash the potential of your customer data. Our AI-driven Intelligent Engagement Platform helps you create intelligent customer journeys and meaningful digital experiences.
- Ovizio — Optimize your process, control your CPPs & monitor quality while reducing hands-on time and risk of contamination.
Epimède SA
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Series B, Series C, Series D
- Belgium, The Netherlands
Portfolio highlights
- Imcyse — Imcyse is a clinical stage biopharmaceutical company pioneering the development of a new class of active specific immunotherapies for the treatment of severe chronic autoimmune diseases. The company’s unique technology platform allows it to locally target immune cells involved in the destruction of the diseased organ. This platform is based on theadministration of Imotopes™, which are specifically modified peptides, allowing for the generation of cytolytic CD4 T-cells, that specifically eliminate antigen-presenting cells and autoantigen specific lymphocytes. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to potentially cure patients without impairing immune defense. The company has established proof of concept in several indications and has completed its first clinical trial in type 1 diabetes with promising results. Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes™ for the treatment of several autoimmune diseases.
- Ncardia — At Ncardia, we believe that human stem cell technology will help get better therapies to patients faster.
- Endo Tools Therapeutics — Endo Tools Therapeutics is dedicated to the development of innovative devices that provide therapeutic interventions for gastric conditions
Qbic is the result of a lot of thinking, debating and sketching of what a city hotel could be; one that breaks the rules and makes people smile.An astonishing level of change has swept through the world over the last few years. But the hotel experience is no different than it’s ever been: stuffy, over-priced and lacking soul. They’re here tochange all that. they’re curious, imaginative and friendly, and they think there are lots of people just like us seeking a hotel with personality in the middle of the city.They believe in something better than what’s currently out there. A place that celebrates life rather than sucks life out of it. A hotel that’s built on creativity and a belief that you don’t have to accept the conventional. Somewhere that sends you away with fun stories and ideas, and is easy on your pocket.
Show more
Investment focus
- Health Care, Biotechnology, AgTech
- Seed, Series B, Funding Round
- Belgium
Portfolio highlights
- moveUP — Ontvang medische zorg op afstand voor en na uw operatie. moveUP is gespecialiseerd in de begeleiding van knie- en heupoperaties.
- Axithra — Axithra provides therapeutic medication monitoring and measures beta-lactam antibiotic concentrations in blood.
- Cascador Health — Cascador Health bridges the gap between sources and users of healthcare data. Using curated, validated and anonymized RWD allows healthcare providers and life science industry to gain insights and provide better care.
Opdorp Finance BVBA
Show more
Investment focus
- Life Science, Data Integration, Data Visualization
- Series A
- Belgium
Portfolio highlights
- ONTOFORCE — ONTOFORCE creates and implements pioneering semantic search technology for information management. Our user-friendly data search platform DISQOVER builds uniquely intelligent links between heterogeneous data sources, allowing everybody to become a data scientist.
OBI SA
Show more
Investment focus
- Life Science, Biotechnology, Health Diagnostics
- Funding Round
- Belgium
Portfolio highlights
- Diagenode — Diagenode is an international life sciences company that develops and commercializes innovative instruments and reagents systems for life science research and molecular diagnostics. Founded in 2003 in Liege (Belgium), Diagenode is a global company, with headquarters in Liege, Belgium and Sparta, NJ, USA. Diagenode also has a local sales office inthe United Kingdom to better serve this specific country.Diagenode's customers include leading epigenetics researchers, academic institutions, high-profile genome centers and core labs, life sciences tools companies, molecular diagnostics players, and pharmaceutical and biotechnology companies.Epigenetics Division
the SRIW Life Sciences
Show more
Investment focus
- Biotechnology, Medical, Biopharma
- Series A, Series B
- Belgium
Portfolio highlights
- A-Mansia Biotech — A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
Our mission is to mature innovation and support the growth of our portfolio companies to create value for patients, society, local ecosystems, and investors.
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Series A, Funding Round, Seed
- Belgium, Japan, France
Portfolio highlights
- AdipoPharma — By harnessing the power of the Adipocyte AdipoPharma is committed to developing innovative treatment for type 2 diabetes
- AbolerIS Pharma — AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance.
- Tensegrity Pharma — Tensegrity Pharma is the developer of a novel drug designed to minimize bottlenecks and provide innovative value to patients.
Innovation Industries is a Dutch venture capital fund investing in impactful deep tech, focusing on sustainability, scalability, and ESG-aligned companies.
Show more
Investment focus
- Semiconductor, Manufacturing, Health Care
- Funding Round, Seed, Series A
- The Netherlands, Belgium, United States
Portfolio highlights
- Carbyon — Carbyon is a Netherlands-based company that develops direct air capture (DAC) technologies. The company's fuels help to replace fossil hydrocarbons with electrical batteries or hydrogen (H2), alternative energy carriers that are used to store renewable electricity and make major changes to transportation facilities, energy grids, and gastransportation networks, filters CO2 from the air and supply it in a purified form to make kerosene for aircraft, enabling existing fossil industry to re-use and repurpose these storage and transport facilities for renewable hydrocarbons.
- Battolyser Systems — Battolyser Systems aims to stimulate the development, production, and commercialization of battolyser technology and is looking for skilled and highly motivated people to join the team. The Company was founded in 2018 by dr. prof Fokko Mulder (Technical University of Delft) together with Kees Koolen (former CEO of Booking.com and former COO ofUber) and is led by CEO Mattijs Slee (previously Shell Hydrogen). The company has a unique patented technology that has the lowest production cost for green hydrogen in the market and does not require scarce materials.
- Nearfield Instruments — Automated High-Throughput 3D Scanning Probe Metrology
invest.bw is a venture capital firm.
Show more
Investment focus
- Health Care, Neuroscience
- Seed
- United States
Portfolio highlights
- BiocSol — BiocSol focus on sustainable microbial-based crop protection.
- VOCSense — VOCSens spin-off is developing a new concept of an environmental camera, EnviCam®, allowing you to see the invisible, those chemical and biochemical molecules that surround us. The company has developed a manufacturing process, CMOSEnvi™, fully compatible with the CMOS technology found in everyday electronic chips.
- neuroClues — An easy-to-use eye-tracking environment to help practitioners instantaneously quantify their clinical exam
Vives is an interregional seed and early stage technology multi-sector fund. The new fund, initiated by UCLouvain, is a unique European inter-university fund having access to world class innovations from leading EU top universities.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Series A, Series B, Funding Round
- Belgium, France, United States
Portfolio highlights
- BOTALYS — BOTALYS uses an innovative Biomimetic Indoor Farming technology to recreate the ideal wild conditions for rare botanicals to grow in. We develop pristine & potent botanical ingredients for the Nutraceutical and Cosmetic industries.
- Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
W.IN.G by Digital Wallonia invests in SAAS, advanced tech and deep tech startups (AI, drones, medtech, IOT,...). W.IN.G brings smart money by helping startups by bi-weekly interactions and providing an operating teams (seasonal entrepreneurs being hands-on with the portfolio).
Show more
Investment focus
- Software, Health Care, Internet
- Seed, Convertible Note, Series A
- Belgium
Portfolio highlights
- IONNYK — IONNYK is a new medium of art photography, containing millions of tiny ink capsules.
- MYOCENE — Myocene is a Liège-based sports technology company which creates unique and innovative devices for measuring muscle fatigue and performance.
- Soil Capital Belgium — Discover Europe's first certified, multi-national carbon farming programme that rewards regenerative agriculture.
VIVES is a seed capital fund initiated by UCLouvain which invests in companies developing disruptive innovations with a positive societal impact.
Show more
Investment focus
- Biotechnology, Therapeutics, Farming
- Seed, Series A
- Belgium, France
Portfolio highlights
- BiocSol — BiocSol focus on sustainable microbial-based crop protection.
- Generare — Harness the ingenuity of nature to transform small molecule discovery
- ATB Therapeutics — ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.
Shaping new life-science ventures.
Show more
Investment focus
- Biotechnology, Therapeutics, Health Care
- Funding Round, Series A, Seed
- The Netherlands, United States, United Kingdom
Portfolio highlights
- Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.
- Tanai Therapeutics — Tanai Therapeutics develops novel therapeutics for people living with obesity and obesity-related complications.
- Brenig Therapeutics — Brenig Therapeutics develops therapies for neurodegenerative disorders.
We are a hands-on investment fund that operates exclusively in the Industry 4.0, energy and new materials sectors. Industrya is an initiative of the John Cockerill industrial group, which joins together the investment funds of SFPI-FPIM, SRIW-WING, NOSHAQ and LRM.
Show more
Investment focus
- Industrial, B2B, SaaS
- Seed, Funding Round
- Belgium, France
Portfolio highlights
- Enosis — Supplier of biological solutions for the production of renewable gas that recycles CO2 through methanation
- Get Your Way — Discover the future of assisted reality with Get Your Way's aRdent smart glasses. Perfect for SMEs looking for innovative solutions to improve their business
- SpotLight — SpotLight provides breakthrough dynamic detection of subsurface movements.
Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Series A, Series B, Funding Round
- France, United States, Germany
Portfolio highlights
- Otoqi — Otoqi is a vehicle delivery platform that develops connected services and logistics solutions for the automotive professionals.
- Siit — Siit is a modern IT service management platform. Conversational, integrated and AI-powered service desk for IT and internal operation teams. Simplify internal operations today!
- Sequentia Biotech — Sequentia Biotech is a bioinformatics company that offers services for healthcare, pharma, agriculture, industry and environment.
6K Venture Capital operates as a venture capital firm.
Show more
Investment focus
- Medical, Software, Health Care
- Seed, Series A
- Panama, Belgium
Portfolio highlights
- Rise Of Defenders — Rise of Defenders is a very interesting Metaverse NFT game, you can use your creativity and tactical thinking to become an excellent player and receive extremely attractive rewards.
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
European Investment Bank (EIB) provides lending, borrowing, and treasury services primarily in the European Union.The company offers project loans for the public and private sectors; loans to banks and other intermediaries; structured finance products; guarantees and securitization instruments for senior and subordinated debts; project bonds;equity and fund investment products such as infrastructure equity and debt funds, and environmental funds; and venture capital funds and security packages for funds.The company also offers microfinance; risk sharing finance for research, development, and innovation projects; finance and technical expertise for sustainable energy projects; infrastructure project advisory services; support for urban development projects; guarantees for transport infrastructure; and funding for public-private partnerships and small- and medium-sized enterprises.EIB serves the transportation, global loans, energy, industry, health, education, water, sewerage, infrastructure, services, telecommunications, agriculture, and fisheries sectors.European Investment Bank was founded in 1958 and is based in Luxembourg.
Show more
Investment focus
- Biotechnology, Health Care, Energy
- Debt Financing, Post-IPO Debt, Funding Round
- France, Germany, The Netherlands
Portfolio highlights
- BURN — The future of clean cooking
- GEWOBA — GEWOBA is a real estate company that manages and provides a diverse portfolio of rental real estate apartments and properties.
- Acea — Acea operates in six business segments. The water segment collects, purchases, transports and distributes drinking water, and manages the sewerage system and the purification of wastewaters. The company serves 9 million residents served in Lazio, Tuscany, Umbria, Molise and Campania; The energy segment manages the transmission and distributesroughly 9 TWh of electricity, public lighting; commercial and trading segment activities include energy management, sale of electricity and gas, energy efficiency for domestic customers. The company is targeting growth in electricity generation from renewable (photovoltaic) sources and in electric mobility, with a view to effectively contributing more and more to the energy transition and decarbonisation. The environment segment provides laboratory, research and related consultancy services on the environment and control functions within the water cycle; engineering services and overseas operations providing water services in Latin America.
UCB Ventures is a €150 million strategic corporate venture fund
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, Belgium, Spain
Portfolio highlights
- ViaNautis — Precision Solutions
- Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
- Switch Therapeutics — Switch Therapeutics is a biotech company dedicated to revolutionizing RNA interference (RNAi) therapies with conditionally activated siRNAs (CASi).
Nivelinvest is a venture capital firm based in Belgium that finances seed stage investments of Small and Medium Enterprises.
Show more
Investment focus
- Biotechnology, iOS, Construction
- Series A, Seed, Funding Round
- Belgium, United States
Portfolio highlights
- CluePoints — CluePoints' Risk-Based Quality Management (RBQM) Software illuminates risks that could compromise patient safety, and enables compliance with ICH E6 (R2).
- A-Mansia Biotech — A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
Fonds Vives II (University of Louvain, UCL)
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Seed
- Belgium, United States
Portfolio highlights
- Virovet — Antiviral drugs and thermostable vaccines for livestock
- Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
- ITeos Therapeutics — iTeos Therapeutics is pioneering the discovery and development of highly differentiated immuno-oncology therapeutics for cancer patients.
Mérieux Développement is specialized in Growth and Venture capital transactions in the healthcare and nutrition sectors. We support companies with products or services offering true differentiation and capacity to create substantial value over the long term. Our investment team, based in Europe and North America, brings its expertise andinternational network to help entrepreneurs disrupt and grasp substantial market opportunities. Mérieux Développement is an affiliate of Institut Mérieux, which employs approximately 17,000 employees worldwide, with consolidated revenues exceeding 2.5 billion Euros in 2017.
Show more
Investment focus
- Health Care, Biotechnology, Medical Device
- Funding Round, Series C, Series B
- France, United States, Belgium
Portfolio highlights
- SeqOne Genomics — Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGShas had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.
- TISSIUM — TISSIUM is creating the future of tissue reconstruction. Learn more about our novel solutions based on our proprietary platform of biomorphic programmable polymers.
- Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Investors by industry
Biotech
Proptech
Gaming
FinTech
Health Care
Community
Google
Marketplace
Climate
Consumer
Artificial intelligence
Impact
Energy
Hardware
EdTech
Sustainability
Venture Capital
Clean Energy
B2B
Real Estate
Publishing
Payments
Big Data
Retail
Organic Food
Web3
Education
Finance
Food and Beverage
Video Games
Infrastructure
Financial Services
Photography
Beauty
Medical
Wellness
Social Media
Social Network
Android
Construction
Art
Local
Legal
Digital Media
Manufacturing
eSports
Sports
Music
Mobile
Internet
Enterprise Software
Franchise
Email
Travel
Mobile Advertising
Biotechnology
Recruiting
Hospitality
Fitness
Platforms
Cannabis
Medical Device
Social
Automotive
Crowdfunding
Wine And Spirits
CleanTech
Mobile Apps
Transportation
InsurTech
Enterprise
LGBT
Fashion
Oil and Gas
Life Science
Film
Theatre
Non Profit
Renewable Energy
SaaS
Sporting Goods
Social Impact
Restaurants
Software
Celebrity
Cryptocurrency
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
India
Germany
South Korea
United Kingdom
Australia
Canada
New Zealand
Ireland
United States
Qatar
Saudi Arabia
Spain
Sri Lanka
China
Middle East
Africa
Indonesia
Europe
Armenia
Singapore
Oceania
Brazil
Japan
South Africa
Vietnam
LATAM
Asia
Denmark
Costa Rica
Bermuda
Egypt
Croatia
Gibraltar
Algeria
Estonia
Ecuador
Greece
Chile
Bulgaria
Ethiopia
Hong Kong
Faroe Islands
France
Ghana
Czech Republic
Hungary
Georgia
Belgium
Finland
Bahrain
Belarus
Belize
Barbados
Lebanon
Mali
Liberia
Malta
Liechtenstein
Malaysia
Italy
Panama
Puerto Rico
Tunisia
Uganda
Myanmar
Sierra Leone
Senegal
San Marino
Uzbekistan
Seychelles
Togo
El Salvador
Rwanda
Russian Federation
Tanzania
Ukraine
Mauritius
Zimbabwe
Uruguay
Nicaragua
Serbia
Taiwan
Venezuela
Tajikistan
Sweden
Turkey
Poland
Thailand
Zambia
Portugal
Slovenia
Philippines
Dominican Republic
Lithuania
Azerbaijan
Iraq
Iceland
Bahamas
Namibia
Israel
Nigeria
United Arab Emirates
Jamaica
Jersey
Norway
Honduras
Morocco
Bolivia
Isle of Man
Luxembourg
Mexico
Peru
Albania
Pakistan
Kuwait
Bangladesh
Argentina
Grenada
Jordan
Romania
Kenya
Kazakhstan
Cayman Islands
Cambodia
Cyprus
Latvia
Oman
Colombia
Cameroon
Austria
Switzerland
Guatemala
Marshall Islands
VC (Venture Capital) Funds in Belgium by industry
Restaurants
Financial Services
Education
Finance
Food and Beverage
Payments
Medical
Wellness
Medical Device
Internet
Social Media
EdTech
Manufacturing
Digital Media
Mobile
Blockchain
Legal
Construction
Software
Sports
Enterprise Software
Hospitality
Automotive
Music
InsurTech
FinTech
Recruiting
Biotechnology
Enterprise
Consumer
Health Care
Biotech
Energy
Sustainability
Impact
SaaS
Marketplace
Artificial intelligence
Community
Gaming
Real Estate
Infrastructure
Fashion
Web3
B2B
Life Science
Publishing
Clean Energy
Renewable Energy
CleanTech
Climate
Transportation
Big Data
Platforms
Proptech
Mobile Apps
Hardware
Media (entertainment)
Cryptocurrency
Agriculture (agtech)
Fitness
Photography
Retail